Nature Communications (Aug 2022)
A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer
- Manijeh Goldberg,
- Aaron Manzi,
- Peter Conway,
- Stefanie Cantin,
- Vasudha Mishra,
- Alka Singh,
- Alexander T. Pearson,
- Eric R. Goldberg,
- Sam Goldberger,
- Benjamin Flaum,
- Rifat Hasina,
- Nyall R. London,
- Gary L. Gallia,
- Chetan Bettegowda,
- Sonya E. O’Neill,
- Erkin Aydin,
- Alex Zhavoronkov,
- Anxo Vidal,
- Atenea Soto,
- Maria Jose Alonso,
- Ari J. Rosenberg,
- Mark W. Lingen,
- Anil D’Cruz,
- Nishant Agrawal,
- Evgeny Izumchenko
Affiliations
- Manijeh Goldberg
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Aaron Manzi
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Peter Conway
- Privo Technologies
- Stefanie Cantin
- Privo Technologies
- Vasudha Mishra
- Department of Medicine, Section of Hematology and Oncology, University of Chicago
- Alka Singh
- Department of Medicine, Section of Hematology and Oncology, University of Chicago
- Alexander T. Pearson
- Department of Medicine, Section of Hematology and Oncology, University of Chicago
- Eric R. Goldberg
- Privo Technologies
- Sam Goldberger
- Privo Technologies
- Benjamin Flaum
- Privo Technologies
- Rifat Hasina
- Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago
- Nyall R. London
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine
- Gary L. Gallia
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine
- Chetan Bettegowda
- Department of Neurosurgery and Oncology, Johns Hopkins University School of Medicine
- Sonya E. O’Neill
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology
- Erkin Aydin
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Alex Zhavoronkov
- Insilico Medicine
- Anxo Vidal
- Department of Physiology, Centro de Investigaciones en Medicina Molecular y Enfermedades Cronicas (CiMUS), Universidade de Santiago de Compostela
- Atenea Soto
- Department of Physiology, Centro de Investigaciones en Medicina Molecular y Enfermedades Cronicas (CiMUS), Universidade de Santiago de Compostela
- Maria Jose Alonso
- Department of Pharmacy and Pharmaceutical Technology, Centro de Investigaciones en Medicina Molecular y Enfermedades Cronicas (CiMUS), Universidade de Santiago de Compostela
- Ari J. Rosenberg
- Department of Medicine, Section of Hematology and Oncology, University of Chicago
- Mark W. Lingen
- Department of Pathology, University of Chicago
- Anil D’Cruz
- Department of Oncology, Apollo Hospital
- Nishant Agrawal
- Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, University of Chicago
- Evgeny Izumchenko
- Department of Medicine, Section of Hematology and Oncology, University of Chicago
- DOI
- https://doi.org/10.1038/s41467-022-31859-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Cisplatin is the most frequently used chemotherapeutic agent for the treatment of patients with oral cavity squamous cell carcinoma (OCSCC), however, systemic administration is often associated with dose limiting side effects. Here the authors design and test a nano-engineered patch system (PRV111) for the local delivery of cisplatin-loaded chitosan nanoparticles and report the results of a phase 1/2 clinical trial of PRV111 in patients with OCSCC.
